Mustang Bio, Inc., a clinical-stage biopharmaceutical company, has amended its previously announced asset purchase agreement with uBriGene Biosciences Inc., the U.S. subsidiary of uBriGene Group, a cell and gene therapy CDMO. uBriGene acquired all of Mustang’s assets primarily relating to the manufacturing and production of cell and gene therapies for a consideration of $6 million in cash. Mustang’s lease to the premises in Worcester, MA where its clinical- and commercial-scale cell and gene ...